ReWalk Robotics Ltd. (NASDAQ:LFWD – Get Free Report) Director Michael Swinford acquired 21,622 shares of the firm’s stock in a transaction dated Monday, November 25th. The shares were purchased at an average price of $2.03 per share, with a total value of $43,892.66. Following the acquisition, the director now owns 65,040 shares of the company’s stock, valued at approximately $132,031.20. This represents a 49.80 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Michael Swinford also recently made the following trade(s):
- On Friday, November 22nd, Michael Swinford bought 16,907 shares of ReWalk Robotics stock. The stock was purchased at an average price of $1.83 per share, for a total transaction of $30,939.81.
- On Wednesday, November 20th, Michael Swinford purchased 16,471 shares of ReWalk Robotics stock. The shares were acquired at an average price of $1.84 per share, with a total value of $30,306.64.
ReWalk Robotics Stock Performance
LFWD stock opened at $2.07 on Friday. The company has a market capitalization of $18.24 million, a P/E ratio of -0.83 and a beta of 2.07. ReWalk Robotics Ltd. has a 52-week low of $1.70 and a 52-week high of $9.10. The business has a 50-day simple moving average of $2.50 and a two-hundred day simple moving average of $3.46.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in ReWalk Robotics stock. Dimensional Fund Advisors LP bought a new position in shares of ReWalk Robotics Ltd. (NASDAQ:LFWD – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 13,548 shares of the company’s stock, valued at approximately $54,000. Dimensional Fund Advisors LP owned approximately 0.16% of ReWalk Robotics as of its most recent SEC filing. 26.76% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “buy” rating and set a $13.00 price objective on shares of ReWalk Robotics in a report on Wednesday, November 13th.
Check Out Our Latest Stock Analysis on ReWalk Robotics
About ReWalk Robotics
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.
Featured Articles
- Five stocks we like better than ReWalk Robotics
- What Are Dividend Achievers? An Introduction
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Penny Stocks Ready to Break Out in 2025
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for ReWalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.